Arrowhead Pharmaceuticals: SHASTA Data Delivers, But Q3 Revenue Collapse And $12.6B Valuation Demand Caution

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported fiscal 2026 third-quarter results today, and the headline is a split screen. On one side, the company announced topline data from its Phase 3 SHASTA-3 and SHASTA-4 trials last week showing plozasiran cut triglycerides by 79–81% versus a 27% placebo reduction, with a statistically significant drop in acute pancreatitis events. The stock has surged from a 52-week low of $15.81 to $89.59 today, up over 440% on a rolling annual basis. On the other side, Q3 revenue was $73.7 million, well below the $160 million consensus estimate, and the company continues to burn cash.

The market has chosen to read the clinical data and largely ignore the quarterly revenue collapse. That may be the right call - or it may be the moment where the stock prices in the best-case regulatory outcome before anyone has paid for the drug. My view is that the SHASTA data is genuinely compelling, but the $12.6 billion market cap demands proof that the sHTG label translates into durable, large-scale revenue. I rate this stock a Hold until the sNDA filing and early commercial signals for the sHTG indication provide clearer visibility.

What changed

Arrowhead's fiscal 2026 third quarter ended June 30, 2026. Revenue was $73.7 million, down from $264 million in Q1 FY2026 and $543 million in Q2 FY2025, the latter driven by a one-time milestone payment. The sharp decline reflects the unwinding of one-time milestone payments, including a $540 million Sarepta payment that drove Q2 FY2025 revenue and elevated comparisons. Consensus had still expected $160 million in Q3, suggesting analysts were pricing in continued milestone or partnership receipts that did not materialize.

The quarter's EPS loss was $0.93 per share, wider than the consensus estimate of $0.74 loss, which means the market's focus was already on the clinical narrative rather than the income statement. The stock jumped 18% on July 22nd when the SHASTA topline data was released and has continued higher, up 42% over the past four months.

The SHASTA results are the core catalyst. Plozasiran - already approved as REDEMPLO for familial chylomicronemia syndrome (a rare disorder affecting roughly 1 in 1 million people) - now has Phase 3 proof in severe hypertriglyceridemia, a much broader population. In patients with triglycerides above 880 mg/dL and a prior history of acute pancreatitis, plozasiran showed a 100% reduction in pancreatitis events versus placebo. The broader population showed a 78% reduction. Arrowhead plans to file a supplemental NDA in the US before the end of 2026, with results to be presented at the European Society of Cardiology Congress on August 30.

The operating picture

Several metrics are worth sitting with.

Revenue growth year-over-year is +14%, but quarter-over-quarter revenue collapsed 72%. Gross margin sits at 100% because Arrowhead's current product, REDEMPLO, has virtually no cost of goods sold - RNAi therapeutics administered as subcutaneous injections are expensive to develop but cheap to manufacture at scale. Operating margin is -36%, EBITDA margin is -31%, and free cash flow over the trailing twelve months is negative $51 million. That compares to free cash flow that was significantly better in the prior year, representing a 630% deterioration.

The company holds $188.5 million in cash with total debt of $1.67 billion, though net debt is negative $903 million when you factor in restricted and investment cash positions. The current ratio is 623%, suggesting no near-term liquidity risk, but the burn rate of roughly $51 million per year is real. At the current pace, Arrowhead's unrestricted cash position of $188 million gives roughly 3–4 years of runway without additional milestone revenue or commercial scale from plozasiran's expanded label.

The pipeline is the real asset. Arrowhead has 20 clinical candidates across its TRiM platform, with partnerships spanning Amgen, Takeda, GSK, Sarepta, and Novartis. Zodasiran for homozygous familial hypercholesterolemia is in Phase 3, and there are early-stage programs in obesity and the central nervous system. Plozasiran itself has three potential indications in the cardiometabolic space: the approved FCS label, sHTG where the SHASTA data just cleared Phase 3, and broader hypertriglyceridemia.

Valuation versus growth and risk

This is where the rating gets complicated. Arrowhead trades at a market cap of $12.6 billion on $622 million of trailing revenue, which works out to roughly 20.3 times sales. For comparison, Alnylam Pharmaceuticals - the other major RNAi developer - trades at 6.1 times sales and has $29.3 billion in market cap. Alnylam benefits from multiple approved products with established commercial revenue. Ionis Pharmaceuticals, another RNA-focused developer, trades at 10.5 times sales on a $9.2 billion market cap.

The point is not that Arrowhead should trade at Alnylam's multiple - the RNAi pipeline is deep and the sHTG market could be transformative. The point is that Arrowhead's revenue multiple already prices in successful regulatory approval, rapid label expansion, and substantial commercial uptake for plozasiran in sHTG. If the sNDA filing is delayed, if pricing or reimbursement encounters friction, or if the commercial ramp for the sHTG label takes longer than the market is currently assuming, that 20x sales multiple has limited room for disappointment.

The catalyst clock

Two near-term events should shape the stock's direction:

1. The ESC Congress presentation on August 30 - Detailed findings from the SHASTA-3 and SHASTA-4 studies will be presented during the European Society of Cardiology Congress in Munich on August 30, 2026. The topline numbers are strong, but full safety and efficacy analysis can sometimes reveal nuances that affect regulatory confidence. This is the first opportunity for the data to be stress-tested by the broader cardiology community.

2. The sNDA filing before year-end 2026 - Arrowhead plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration before the end of 2026. The timing and completeness of this filing will signal regulatory readiness. A PDUFA date (the FDA review deadline) would likely point to a decision window in mid-2027.

Beyond that, the commercial trajectory for sHTG will depend on payer adoption, pricing, and competition. Positive payer feedback following price adjustment for REDEMPLO in its narrow FCS indication. Whether that translates to smoother formulary access in the much larger sHTG population remains to be seen.

Risks

The main risk is that the market is pricing in sHTG approval and commercial success before the regulatory filing has even been submitted. A $12.6 billion market cap for a company generating $622 million in annual revenue and burning $51 million in annual free cash flow is a vote of confidence in plozasiran's expansion - but it is also a valuation that leaves limited margin for error.

Additional risks include:

• Regulatory timing: The sNDA filing is a management commitment, not a guarantee. Submission delays or requests for additional data could push approval well beyond 2027.
• Reimbursement: The sHTG population is larger than FCS but less rare, meaning payers will demand more rigorous cost-effectiveness evidence before covering a drug priced at orphan-drug levels.
• Competitive pressure: Antisense oligonucleotide (ASO) therapies and other lipid-lowering approaches are in development. Arrowhead's management has noted that liver-fat increases and thrombocytopenia (low platelets) are more characteristic of ASO class effects, positioning plozasiran as cleaner on safety, but competitors are not standing still.
• Cash burn: Negative $51 million in trailing free cash flow is manageable for now but constrains flexibility if milestone revenue stalls and plozasiran's expanded label is delayed.

Conclusion

The SHASTA Phase 3 data is the kind of clean readout that moves a biotech stock. Triglyceride reductions of 79–81%, a 100% reduction in pancreatitis events in the highest-risk subgroup, and no new safety signals are exactly the results investors want to see from a Phase 3 program. Arrowhead's management team has earned credibility through the FCS approval and multiple global registrations.

But the $89.59 share price and $12.6 billion market cap already reflect a scenario where the sNDA is filed on time, approved without major hesitation, priced at a premium, and adopted rapidly by payers. The Q3 revenue collapse to $74 million versus $160 million in consensus - and the continued cash burn - are signals that the near-term financials do not yet support the valuation.

I rate Arrowhead a Hold. The clinical data is strong enough that I do not want to stand on the wrong side of a genuine platform story, but the valuation has outrun the current evidence base. The investor who bought near the $16 low has a 450% gain that is now at risk of a sharp pullback if the sHTG label faces any meaningful delay. The new investor at $90 is paying for a best-case timeline before the filing is even in the door.

What would move me to Buy is a successful sNDA filing followed by clear regulatory momentum - a PDUFA date in early 2027 with management signaling pricing and payer confidence. What would move me to Sell is a filing delay, a negative safety signal in the detailed ESC data, or evidence that payer adoption for the sHTG label is more difficult than the company's current commentary suggests.

The catalyst clock is set. The question for investors is whether they want to hold through the next 12–18 months of regulatory uncertainty at a price that already assumes things go right.